A randomized comparison of acitretin-narrow-band TL-01 phototherapy and acitretin-psoralen plus ultraviolet A for psoriasis. 2008

Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
Department of Dermatology, Meram Medical Faculty, Selcuk University, Konya, Turkey. mustafaozdemir@yahoo.com

The combination of retinoids with phototherapy enhances the efficacy of phototherapy and reduces the cumulative ultraviolet dose and duration of the therapy needed to treat chronic plaque psoriasis. Although TL-01 phototherapy has been used widely, there are few data about the effectiveness of the combination of acitretin with TL-01 in treatment of the disease. The aim of this study was to compare acitretin-narrow-band TL-01 phototherapy with acitretin-psoralen plus ultraviolet A (acitretin-PUVA) in psoriasis. We studied 60 patients with moderate to severe plaque psoriasis who were randomly allocated to three times weekly treatment acitretin-narrow-band TL-01 or acitretin-PUVA. The efficacy of treatments was assessed using the Psoriasis Area and Severity Index by a blinded observer. Clearance of psoriasis was achieved in 56.6% of patients treated with acitretin-narrow-band TL-01 and in 63.3% of those treated with acitretin-PUVA. All of these patients remained clear of psoriasis 3 months after finishing the treatments. Mucocutaneous side-effects, such as dry lips and mouth, were the most common complaints in both groups. In conclusion, acitretin-narrow-band TL-01 is an effective and well-tolerated treatment for moderate to severe plaque psoriasis, with a therapeutic effect equal to that of acitretin-PUVA.

UI MeSH Term Description Entries
D007641 Keratolytic Agents Agents that soften, separate, and cause desquamation of the cornified epithelium or horny layer of skin. They are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. Desquamating Agents,Skin-Peeling Agents,Agents, Desquamating,Agents, Keratolytic,Agents, Skin-Peeling,Skin Peeling Agents
D008297 Male Males
D010789 Phototherapy Treatment of disease by exposure to light, especially by variously concentrated light rays or specific wavelengths. Blue Light Therapy,Blue-light Therapy,Light Therapy,Photoradiation Therapy,Red Light Phototherapy,Therapy, Photoradiation,Blue Light Therapies,Blue-light Therapies,Light Phototherapies, Red,Light Phototherapy, Red,Light Therapies,Light Therapies, Blue,Light Therapy, Blue,Photoradiation Therapies,Phototherapies,Phototherapies, Red Light,Phototherapy, Red Light,Red Light Phototherapies,Therapies, Blue Light,Therapies, Blue-light,Therapies, Light,Therapies, Photoradiation,Therapy, Blue Light,Therapy, Blue-light,Therapy, Light
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011701 PUVA Therapy Photochemotherapy using PSORALENS as the photosensitizing agent and ultraviolet light type A (UVA). Psoralen Ultraviolet A Therapy,Therapy, PUVA,PUVA Therapies,Therapies, PUVA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
November 1999, Journal of the American Academy of Dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
June 2001, The British journal of dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
January 2004, Clinical and experimental dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
October 2013, The Cochrane database of systematic reviews,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
February 2000, The British journal of dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
May 1998, The British journal of dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
December 2009, Journal of the European Academy of Dermatology and Venereology : JEADV,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
October 1992, The British journal of dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
August 1998, The Australasian journal of dermatology,
Mustafa Ozdemir, and Burhan Engin, and Ibrahim Baysal, and Inci Mevlitoğlu
February 2006, Journal of the European Academy of Dermatology and Venereology : JEADV,
Copied contents to your clipboard!